Please login to the form below

F-Star

This page shows the latest F-Star news and features for those working in and with pharma, biotech and healthcare.

Cancer disruptor F Star names next CEO

Dr Eliot Forster takes reins from Dr John Haurum. UK-based biotech F-star has named Dr Eliot Forster as its new chief executive. ... I believe that F-star’s first-in-class molecules bring together in a single form, the full power of IO and combinations.

Latest news

BMS taps F-star Alpha for immuno-oncology drug

Drug in development for breast and stomach cancers. Bristol-Myers Squibb (BMS) has hatched a plan to buy Austrian biotech F-star Alpha in order to claim rights to FS102, a ... F-star has its headquarters in Vienna but runs its research operations out of
f-star wins €15m investment

Antibody specialist f-star secures funding from existing investors and adds new members to its supervisory board. ... f-star, a company developing antibody-based products, has secured 15m of new financing.
Survival strategy

During November and December 2010 there were five Big Pharma discovery deals involving Boehringer Ingelheim (with f-star), S-A (with Avila Therapeutics), Pfizer (with Phylogica), Tanabe Research Laboratories (with Anaphore) ... f-star/Boehringer
PM Society Awards 2005

These days you're lucky if you can give them a three-star hotel and a f ing biro. ... He also issued a thinly-veiled warning to any entrants who had been honoured with a highly commended': Congratulations and all that but stay in your f ing seat.

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest Intelligence

Deal Watch table for October 2014

525. F-star Alpha/BMS. Option to acquire F-star Alpha. Includes FS102 a P1 ready treatment for HER2 positive patients with breast / gastric cancer.
Pharma deals during October 2014

A major feature throughout 2014 has been the deployment of options. This month is no exception with Bristol-Myers Squibb (BMS) securing an exclusive option to acquire F-star Alpha gaining

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

New hires at FibroGen, Saniona and Turbine

Previously, she held the position of senior vice president of drug discovery at F-star, overseeing all internal and collaborative bispecific antibody discovery programmes.
F-star hires ex-BMS immuno-oncology leader

I believe F-star is ideally positioned to become the next leader in this field.”. ... Eliot Forster, CEO of F-star, said: “We are delighted to welcome Louis to the F-star team.
Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO

Jallal will succeed Andrew Hotchkiss, who has served as interim CEO after Eliot Forster (pictured above) left the company to head up cancer disrupter F Star last year.
ImmuneXcite boosts senior leadership

Edwards is currently executive chairman at F-star, having previously served as its chief executive officer, and brings over 30 years of biotechnology expertise from Adnexus Therapeutics, Genetics Institute/Wyeth and
F-star appoints vice president of protein sciences

Mike Davies joins from CPI Biologics. Vienna-headquartered biopharmaceutical company F-star has appointed Mike Davies as vice president of protein sciences at its Cambridge, UK research site. ... John Haurum, chief executive officer of F-star, said:

More from appointments
Approximately 3 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

claire@dovetailstrategies.com

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

Surviving cancer: a new era for patients: Now more than ever, a shift in perspective is needed...
Crisis? No problem!: Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?: First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....